CD19 and classic Hodgkin lymphoma: Despite HRS cells’ lack of CD19 expression, it has been hypothesized that also anti-CD19 CAR T-cells could have a certain antitumor activity in cHL due to targeting of the non-malignant B-cells included in the TME and of the CD19-positive clonotypic B-cells thought to be responsible for the continued generation of HRS cells [157,158].